Entity

Time filter

Source Type


Zhao Z.-B.,Shenyang University | Guan D.-W.,Shenyang University | Liu W.-W.,Shenyang University | Wang T.,Shenyang University | And 4 more authors.
Journal of Forensic Medicine | Year: 2010

Objective To investigate the expression of cannabinoid receptor I (CB1R) during mice skin incised wound healing course and time-dependent changes of CB1R in wound age determination. Methods The changes of CB1R expression in skin incised wound were detected by immunohistochemistry and Western blotting. Results The control group showed a low expression of CB1R detected mainly in epidermis, hair follicles, sebaceous gland and dermomuscular layer. CB1R expression was undetectable in neutrophils in the wound specimens from 6 h to 12 h post-injury. CB1R positive cells were mostly mononuclear cells (MNCs) and fibroblastic cells(FBCs) from Id to 5 d post-injury. CB1R positive cells were mostly FBCs from 7 d to 14 d post-injury. The ratio of the CB1R positive cells increased gradually in the wound specimens from 6 h to 3d post-injury, reached peak level at 5 d, and then decreased gradually from 7 d to 14 d post-injury. The positive bands of CB1R were observed in all time points of the wound healing course by Western blotting. The expression peak showed at 5 d post-injury. Conclusion CB1R is activated during the wound healing course. The expression of CB1R is found in mononuclear cells, which could be involved in inflammation reaction. CB1R is observed in fibroblastic cells, which could participate in the wound healing. CB1R may be a potentially useful marker for determination of wound healing age. Source


Cheng Z.,Shenyang University | Cheng Z.,Forensic Science Identification Center | Guan D.,Shenyang University | Yu T.,Shenyang University | And 3 more authors.
Chinese Journal of Forensic Medicine | Year: 2010

Objective: To investigate the expression of p-CB1R during wound healing of skeletal muscle contusion in rats and to explore the applicability of p-CB1R to wound age estimation. Methods: A total of 50 male, healthy rats, weighting 220 ∼ 250g were divided into 10 groups randomly. The changes of p-CB1R expression were assessed by immunostaining and Western blotting. Results: The expression of p-CB1R was neither detected in skeletal muscle fibers in control rats nor wounded skeletal muscle. No-immunoreactivity of p-CB1R was detected in polymorphonuclear cells (PMNs) in the wound specimens. p-CB1R-positive immunostaining was detected in mononuclear cells (MNCs) in the wounded specimens aged from 3h to 1d. From 3d to 5d postwounding, p-CB1R-immunoreactivity was mainly found in MNCs and fibroblastic cells (FBCs), and mainly in FBCs from 7d to 10d postwounding with a peak at the 7d and then decreased at 14d. A similar tendency for p-CB1R protein changes was noted as determined by Western blotting. Conclusion: p-CB1R is time-dependently expressed in MNCs and FBCs during wound healing of skeletal muscle contusion in rats, suggesting that it may be used as a marker for wound age determination. Source


Mu H.-F.,CAS Beijing Institute of Genomics | Xu D.,Criminal Police Branch | Liu B.,Forensic Science Identification Center | Huang Y.-Q.,CAS Beijing Institute of Genomics | And 3 more authors.
Journal of Forensic Medicine | Year: 2013

Objective: To study the suspected autosomal STR loci mutation cases. Methods: A total of 227 suspected autosomal STR loci mutation cases were selected from Center of Forensic Sciences, Beijing Genomics Institute. The allelic mutation cases were screened and the number of mutation of each STR loci was statistically analyzed. The CPI value was calculated in order to study the characteristics and rules of the mutations. Results: In the 227 suspected mutation cases, 3 cases were excluded paternity, and 228 mutations were observed at 18 STR loci in the rest of the cases. The average number of STR mutation loci was 1-2. The maximum of mutation step was 4. After using 20A amplification kit, the CPI values in 3 non-parentage cases were all less than 104. After using 20A and 10G amplification kits, the CPI values were all larger than 104 in all standard parents-child triplet cases and in 99.45% of diad cases. Conclusion: The allelic mutation of STR loci is relatively common in forensic cases. By increasing the number of the required STR loci and supplementing the samples of the triplet, the identification errors could be decreased to a great extent when suspected autosomal STR loci mutation occurs. Copyright © 2013 by the Editorial Department of Journal of Forensic Medicine. Source


Guo X.,Shanxi Medical University | Zhai L.,Shanxi Medical University | Xue R.,Forensic Science Identification Center | Shi J.,Shanxi Medical University | And 2 more authors.
International Journal of Molecular Sciences | Year: 2016

Pancreatic cancer is a highly lethal malignancy and one of the leading causes of cancer-related death. During the development and progression of cancer, tumor angiogenesis plays a crucial role. A great deal of evidence has revealed that human mast cells (MCs) contributed to tumor angiogenesis through releasing several pro-angiogenetic factors, among which tryptase is one of the most active. However, the role of mast cell tryptase (MCT) in human pancreatic cancer angiogenesis is still not well documented. In this study, we examined the MCT levels in serum from pancreatic cancer patients and evaluated the correlationship of the MCT level and tumor angiogenesis. In addition, the effect of MCT on endothelial cell proliferation and tube formation was investigated both in vitro and in nude mice bearing pancreatic tumor. It was found that MCT contributes to endothelial cell growth and tube formation via up-regulation of angiopoietin-1 expression. Moreover, using the MCT inhibitor nafamostat, tryptase-induced angiogenesis was obviously suppressed both in vitro and in vivo. Our findings suggest that MCT plays an important role in pancreatic cancer angiogenesis and tumor growth via activating the angiopoietin-1 pathway, and tryptase inhibitors may be evaluated as an effective anti-angiogenetic approach in pancreatic cancer therapy. © 2016 by the authors; licensee MDPI, Basel, Switzerland. Source

Discover hidden collaborations